The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

19 articles for S Howard


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.EBI
Translational Research Institute
Structure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper Kinase.EBI
Astex Pharmaceuticals
Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinase.EBI
Astex Pharmaceuticals
Fragment-based discovery of 6-azaindazoles as inhibitors of bacterial DNA ligase.EBI
Astex Pharmaceuticals
Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors.EBI
TBA
Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2.EBI
Astex Pharmaceuticals
A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-oneEBI
Astex Pharmaceuticals
HIF-1α inhibitor, preparation method therefor, and pharmaceutical composition for preventing or treating angiogenesis-associated eye disease, containing same as active ingredientBDB
Seoul National University
CYCLIN INHIBITORSBDB
Circle Pharma
Heterocyclic compounds for the inhibition of PASKBDB
Bioenergenix
PARG inhibitory compoundsBDB
Cancer Research Technology
4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitorsBDB
TBA
Fused heteroaryl derivatives as orexin receptor antagonistsBDB
Merck, Sharp & Dohme
Negative allosteric modulators of metabotropic glutamate receptor 3BDB
Vanderbilt University
Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonistsBDB
Heptares Therapeutics
Mild and efficient synthesis of new tetraketones as lipoxygenase inhibitors and antioxidants.BDB
Pharmaceutical Research Centre
Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT3 receptor revealed.BDB
Vrije Universiteit
Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues.BDB
University of Bologna